Circulating Pv-1 As A Marker of Celiac Disease-Associated Liver Injury

Leo, Luigina De; Naviglio, Samuele; Vatta, Serena; Benelli, Elisa; Stera, Giacomo; Santon, Daniela; Ziberna, Fabiana; Taddio, Andrea; Martelossi, Stefano; Giudici, Fabiola; Giuffrida, Paolo; Sabatino, Antonio Di; Corazza, Gino Roberto; Ventura, Alessandro; Not, Tarcisio

doi:10.2217/bmm-2020-0281

Cited by 5 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The analysis included serum cytokines (interleukins; IL-1β, IL-12RA, IL-6, IL-8 and tumor necrosis factor, TNF-α) measured using Ella™ (Bio-Techne, Oxford, UK) [ 37 , 38 ], and serum markers of intestinal barrier integrity and permeability including zonulin, citrulline and plasmalemmal Vesicle Associated Protein-1, PV-1 assessed by ELISA test [ 26 , 27 , 28 , 39 ]. Blood samples were collected before (T 0 ) and after the 8 weeks (T 1 ) of treatment in a vial without anticoagulant to obtain serum.…”

Section: Methodsmentioning

confidence: 99%

Ecology and Machine Learning-Based Classification Models of Gut Microbiota and Inflammatory Markers May Evaluate the Effects of Probiotic Supplementation in Patients Recently Recovered from COVID-19

Laterza

Putignani

Settanni

et al. 2023

IJMS

View full text Add to dashboard Cite

Gut microbiota (GM) modulation can be investigated as possible solution to enhance recovery after COVID-19. An open-label, single-center, single-arm, pilot, interventional study was performed by enrolling twenty patients recently recovered from COVID-19 to investigate the role of a mixed probiotic, containing Lactobacilli, Bifidobacteria and Streptococcus thermophilus, on gastrointestinal symptoms, local and systemic inflammation, intestinal barrier integrity and GM profile. Gastrointestinal Symptom Rating Scale, cytokines, inflammatory, gut permeability, and integrity markers were evaluated before (T0) and after 8 weeks (T1) of probiotic supplementation. GM profiling was based on 16S-rRNA targeted-metagenomics and QIIME 2.0, LEfSe and PICRUSt computational algorithms. Multiple machine learning (ML) models were trained to classify GM at T0 and T1. A statistically significant reduction of IL-6 (p < 0.001), TNF-α (p < 0.001) and IL-12RA (p < 0.02), citrulline (p value < 0.001) was reported at T1. GM global distribution and microbial biomarkers strictly reflected probiotic composition, with a general increase in Bifidobacteria at T1. Twelve unique KEGG orthologs were associated only to T0, including tetracycline resistance cassettes. ML classified the GM at T1 with 100% score at phylum level. Bifidobacteriaceae and Bifidobacterium spp. inversely correlated to reduction of citrulline and inflammatory cytokines. Probiotic supplementation during post-COVID-19 may trigger anti-inflammatory effects though Bifidobacteria and related-metabolism enhancement.

show abstract

Section: Methodsmentioning

confidence: 99%

Ecology and Machine Learning-Based Classification Models of Gut Microbiota and Inflammatory Markers May Evaluate the Effects of Probiotic Supplementation in Patients Recently Recovered from COVID-19

Laterza

Putignani

Settanni

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…However, it consistently demonstrates that PLVAP could be used as a histological marker of glomerular endothelial injury in DM that seems superior to other endothelial markers such as CD31 or ERG. Interestingly, circulating PLVAP was reported as a serum marker of celiac disease-associated liver injury in humans [ 45 ]. This finding opens the possibility for using PLVAP levels in body fluids like serum or urine as an unsophisticated diagnostic readout of microvascular injury in diabetic patients.…”

Section: Discussionmentioning

confidence: 99%

PLVAP as an Early Marker of Glomerular Endothelial Damage in Mice with Diabetic Kidney Disease

Wolf

Steglich

Kessel

et al. 2023

IJMS

View full text Add to dashboard Cite

Plasmalemma vesicle-associated protein (PLVAP) is the main component of endothelial diaphragms in fenestrae, caveolae, and transendothelial channels. PLVAP is expressed in the adult kidney glomerulus upon injury. Glomerular endothelial injury is associated with progressive loss of kidney function in diabetic kidney disease (DKD). This study aimed to investigate whether PLVAP could serve as a marker for glomerular endothelial damage in DKD. Glomerular PLVAP expression was analyzed in different mouse models of DKD and their respective healthy control animals using automatic digital quantification of histological whole kidney sections. Transgenic mice expressing a dominant-negative GIP receptor (GIPRdn) in pancreatic beta-cells as a model for diabetes mellitus (DM) type 1 and black and tan brachyuric (BTBR) ob/ob mice, as a model for DM type 2, were used. Distinct PLVAP induction was observed in all diabetic models studied. Traces of glomerular PLVAP expression could be identified in the healthy control kidneys using automated quantification. Stainings for other endothelial injury markers such as CD31 or the erythroblast transformation-specific related gene (ERG) displayed no differences between diabetic and healthy groups at the time points when PLVAP was induced. The same was also true for the mesangial cells marker α8Integrin, while the podocyte marker nephrin appeared to be diminished only in BTBR ob/ob mice. Glomerular hypertrophy, which is one of the initial morphological signs of diabetic kidney damage, was observed in both diabetic models. These findings suggest that PLVAP is an early marker of glomerular endothelial injury in diabetes-induced kidney damage in mice.

show abstract

“…Thus, PV-1 serum measurement could represent a potential diagnostic tool for liver injury in CD. At the same time, the absence of mucosal PV-1 expression in CD patients led researchers to hypothesize a hepatic vascular origin of PV-1 rather than intestinal, in contrast with the work by Spadoni et al [ 36 , 138 ]. Since PV-1 expression in liver sinusoidal endothelial cells is documented in vivo [ 139 ], further studies are needed to confirm the hepatic origin of serum PV-1 in celiac disease.…”

Section: Gut–vascular Barrier In Celiac Diseasementioning

confidence: 98%

The Gut–Vascular Barrier as a New Protagonist in Intestinal and Extraintestinal Diseases

Tommaso

Santopaolo

Gasbarrini

et al. 2023

IJMS

View full text Add to dashboard Cite

The intestinal barrier, with its multiple layers, is the first line of defense between the outside world and the intestine. Its disruption, resulting in increased intestinal permeability, is a recognized pathogenic factor of intestinal and extra-intestinal diseases. The identification of a gut–vascular barrier (GVB), consisting of a structured endothelium below the epithelial layer, has led to new evidence on the etiology and management of diseases of the gut–liver axis and the gut–brain axis, with recent implications in oncology as well. The gut–brain axis is involved in several neuroinflammatory processes. In particular, the recent description of a choroid plexus vascular barrier regulating brain permeability under conditions of gut inflammation identifies the endothelium as a key regulator in maintaining tissue homeostasis and health.

show abstract

Circulating Pv-1 As A Marker of Celiac Disease-Associated Liver Injury

Cited by 5 publications

References 30 publications

Ecology and Machine Learning-Based Classification Models of Gut Microbiota and Inflammatory Markers May Evaluate the Effects of Probiotic Supplementation in Patients Recently Recovered from COVID-19

Ecology and Machine Learning-Based Classification Models of Gut Microbiota and Inflammatory Markers May Evaluate the Effects of Probiotic Supplementation in Patients Recently Recovered from COVID-19

PLVAP as an Early Marker of Glomerular Endothelial Damage in Mice with Diabetic Kidney Disease

The Gut–Vascular Barrier as a New Protagonist in Intestinal and Extraintestinal Diseases

Contact Info

Product

Resources

About